Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
J Dairy Sci ; 102(4): 2844-2853, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30799108

ABSTRACT

Synbiotics, a combination of prebiotics and probiotics, produce synergistic effects to promote gastrointestinal health. Herein, we investigated the synbiotic interaction between the Lactobacillus rhamnosus strain GG (LGG; a probiotic strain) and tagatose (a prebiotic) in a dextran sulfate sodium (DSS)-induced colitis murine model. Initially, body weight, food intake, and clinical features were dramatically decreased after treatment with DSS, and the addition of LGG, tagatose, or both ameliorated these effects. In our pyrosequencing analysis of fecal microbiota, DSS treatment increased the abundance of Proteobacteria and decreased that of Firmicutes. When LGG and tagatose were administered as synbiotics, the gut microbiota composition recovered from the dysbiosis caused by DSS treatment. In particular, the abundance of Bacteroides, Lactobacillus, and Akkermansia was significantly associated with probiotic, prebiotic, and synbiotic treatments. Taken together, our results suggest that LGG and tagatose as synbiotics can alleviate colitis, and synbiotics could be applied as dietary supplements in dairy foods such as yogurt and cheese.


Subject(s)
Colitis/chemically induced , Colitis/therapy , Hexoses/therapeutic use , Lacticaseibacillus rhamnosus , Synbiotics , Animals , Dextran Sulfate/toxicity , Feces/microbiology , Hexoses/administration & dosage , Iron Chelating Agents/administration & dosage , Iron Chelating Agents/pharmacology , Lactobacillus , Lacticaseibacillus rhamnosus/classification , Mice , Microbiota
2.
Scand J Rheumatol ; 48(3): 198-206, 2019 May.
Article in English | MEDLINE | ID: mdl-30475093

ABSTRACT

OBJECTIVE: The aim was to investigate prevalence and degree of ocular and oral involvement in patients with primary Sjögren's syndrome (PSS). METHOD: We analysed 134 participants from the Korean Initiative of PSS cohort who completed a 2 year follow-up oral and ocular sign test. The severity of keratoconjunctivitis sicca (KCS) was determined with the Schirmer I test value (STV) [abnormal (AB) ≤ 5 mm/5 min; normal (N) > 5 mm/5 min]. Salivary gland dysfunction (SGD) was determined by unstimulated whole salivary (UWS) flow rate [moderate to severe (MS) < 0.1 mL/min; mild (Mi) ≥ 0.1 mL/min]. Subgroups were divided into three groups according to STV and severity of SGD: AB-STV/MS-SGD, AB-STV/Mi-SGD, and N-STV/MS-SGD groups. We analysed the changes in STV and SGD during the follow-up period. RESULTS: Among the 134 participants enrolled in this study, 105 (78%) were placed in the AB-STV/MS-SGD group, 16 (12%) in the AB-STV/Mi-SGD, and 13 (10%) in the N-STV/MS-SGD at the 2 year follow-up. The AB-STV/Mi-SGD group was younger than the other two groups, and had a lower Xerostomia Inventory score and lower level of ß2-microglobulin. Participants in the N-STV/MS-SGD group had less hyperimmunoglobulinaemia, rheumatoid factor (RF), and antinuclear antibodies (ANAs). Patients and those with positive RF or ANA ≥ 1:320 at baseline were more likely to have abnormal STV at the 2 year follow-up. CONCLUSIONS: Patients with PSS and positive RF or ANA ≥ 1:320 at baseline may benefit from regular ophthalmology examinations, even if they do not have KCS at baseline or dry eye symptoms.


Subject(s)
Keratoconjunctivitis Sicca , Sjogren's Syndrome/complications , Xerostomia , Adult , Age Factors , Antibodies, Antinuclear/blood , Cohort Studies , Female , Humans , Keratoconjunctivitis Sicca/diagnosis , Keratoconjunctivitis Sicca/etiology , Keratoconjunctivitis Sicca/immunology , Male , Middle Aged , Prevalence , Republic of Korea/epidemiology , Rheumatoid Factor/blood , Severity of Illness Index , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/epidemiology , Symptom Assessment , Xerostomia/diagnosis , Xerostomia/etiology , Xerostomia/immunology
3.
Anaesthesia ; 74(1): 51-56, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30383296

ABSTRACT

Several studies have investigated the effects of general anaesthesia on neurodevelopment in children, with conflicting results. The potential for early general anaesthesia exposure to impact neurodevelopment in children may cause significant concern for parents. Administering a questionnaire in 200 parents, we aimed to explore their knowledge, concerns and perceptions, and determine factors which influence parents' willingness for their children to participate in relevant research studies. A significant proportion of parents (40%) were concerned that general anaesthesia may affect their child's neurodevelopment. Generally these concerns arose from the parents' own beliefs or preconceived ideas and only 25.5% had encountered prior information in this domain. Parents with children aged 2 years or younger, those whose children had previous general anaesthesia exposure, and those who had encountered information about potential neurodevelopmental effects were most likely to be concerned. The majority of parents (68%) would agree to participate in research studies, especially if they were able to receive the test results. Anaesthetists should pre-emptively initiate discussions to address any potential misconceptions regarding the effects of general anaesthesia on neurodevelopment in children.


Subject(s)
Anesthesia, General/adverse effects , Anesthetics, General/adverse effects , Developmental Disabilities/chemically induced , Nervous System/growth & development , Parents , Adolescent , Adult , Child , Child, Preschool , Cross-Sectional Studies , Female , Health Knowledge, Attitudes, Practice , Humans , Infant , Male , Singapore , Socioeconomic Factors , Surveys and Questionnaires
4.
J Dent Res ; 96(12): 1414-1421, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28665757

ABSTRACT

We recently reported the presence of anti-aquaporin 5 (AQP5) immunoglobulin G (IgG) in patients with primary Sjögren syndrome (SS) with a sensitivity of 0.73 and a specificity of 0.68. The aim of this study was to identify functional epitopes for the anti-AQP5 autoantibodies detected in control subjects and patients with SS. Recognition of epitopes by anti-AQP5 autoantibodies in sera ( n = 13 for control and n = 24 for SS) or purified IgG ( n = 1 for control and n = 3 for SS) was evaluated by indirect immunofluorescence (IIF) assay performed in the presence or absence of peptides corresponding to the second transmembrane helix and extracellular loops A, C, and E of AQP5. Functional epitopes were determined by measuring the effects of purified IgG and neutralizing peptides on transepithelial osmotic permeability (PfT) of MDCK cells expressing AQP5. In the IIF assay, 89% of SS samples were inhibited by at least 1 peptide, while only half of control samples were inhibited by any peptide. Overall, SS samples were inhibited by peptides corresponding to extracellular loops A, C, and E by 40% to 50%, whereas control samples were inhibited only by peptides corresponding to loop E by <20%. A cyclized peptide (E1) mimicking loop E was most frequently recognized and best differentiated between the SS and control samples. Incubation of MDCK-AQP5 cells with SS but not with control IgG, significantly decreased PfT, which was reversed by neutralization of IgG binding to any of the extracellular loops. In conclusion, the anti-AQP5 autoantibodies detected in control and SS groups showed differences in fine specificity to the functional epitopes of AQP5. The prevalent recognition of functional epitopes by anti-AQP5 autoantibodies from SS patients suggests that anti-AQP5 autoantibodies act as mediators of glandular hypofunction and are a potential therapeutic target in SS.


Subject(s)
Aquaporin 5/antagonists & inhibitors , Epitopes/immunology , Sjogren's Syndrome/immunology , Amino Acid Sequence , Autoantibodies/immunology , Fluorescent Antibody Technique, Indirect , Humans , Immunoglobulin G/immunology , Peptides/immunology
5.
Osteoporos Int ; 28(11): 3251-3259, 2017 11.
Article in English | MEDLINE | ID: mdl-28748389

ABSTRACT

The risk factors for atypical femur fracture in patients exposed to bisphosphonates for at least 1 year were examined. Prolonged and continuous use of bisphosphonates, long-term use of glucocorticoids, and a higher body mass index were associated with increased risk of atypical femur fracture. INTRODUCTION: The purpose of the present study is to determine whether rheumatoid arthritis (RA) and other clinical factors are associated with an increased risk of bisphosphonate (BP)-related atypical femur fracture (AFF). METHODS: A retrospective nested case-control study of patients who had taken BPs for at least 1 year was conducted. Patients with AFF were identified by reviewing surgical and radiographic records. Three controls with no history of AFFs were randomly selected and age- and sex-matched to each patient with AFFs. Cox proportional hazard models were used to analyze the independent contribution of risk factors to BP-related AFF. RESULTS: Among the 35,104 patients prescribed BPs for at least 1 year, 43 females (mean age, 68 years) suffered AFFs (0.12%). Patients with AFFs were exposed to BPs for a mean of 7.3 years. Patients with AFFs were exposed to BPs for longer than those without AFFs and continued treatment without a drug holiday. More patients with AFF than controls had taken glucocorticoids and disease-modifying anti-rheumatic drugs. Multivariate Cox regression analyses estimated that long-term use of glucocorticoids, prolonged exposure to BP without cessation, and every 1 kg/m2 increase in the body mass index (BMI) increased the hazard ratio for AFFs by 3.0, 5.2, and 1.2, respectively. CONCLUSIONS: Prolonged and continuous use of BPs, long-term use of glucocorticoids, and a higher BMI increase the risk of AFFs. Switching long-term BP and glucocorticoid users to other bone-protective agents should be considered.


Subject(s)
Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Femoral Fractures/chemically induced , Absorptiometry, Photon/methods , Aged , Bone Density/drug effects , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/therapeutic use , Diphosphonates/administration & dosage , Diphosphonates/therapeutic use , Drug Administration Schedule , Female , Femoral Fractures/diagnostic imaging , Femoral Fractures/physiopathology , Glucocorticoids/adverse effects , Humans , Middle Aged , Osteoporosis, Postmenopausal/drug therapy , Radiography , Retrospective Studies , Risk Factors
6.
Scand J Rheumatol ; 46(1): 49-55, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27098775

ABSTRACT

OBJECTIVES: Fatigue is a common clinical manifestation in patients with primary Sjögren's syndrome (pSS). The aims of this study were to investigate the association between fatigue severity and other clinical characteristics in pSS patients and to determine the factors contributing to fatigue. METHOD: We analysed 257 participants from the Korean Initiative of pSS (KISS), a prospective pSS cohort. Fatigue was assessed according to the fatigue domain of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient-Reported Index (ESSPRI). Health-related quality of life (HRQoL) was evaluated using the EuroQol-5 dimensions (EQ-5D) questionnaire. Multiple linear regression analysis was used to estimate the effect of each variable on fatigue severity. RESULTS: The median total ESSPRI score was 5 [interquartile range (IQR) 4-6]. Thirty-four per cent of patients reported a fatigue score > 5. Younger and premenopausal patients presented with more fatigue (p = 0.013 and p < 0.001, respectively). Higher Xerostomia Inventory (XI) scale (p < 0.001) and Ocular Surface Dryness Index (OSDI) (p < 0.001) scores were observed in patients with a fatigue score > 5. Pain, xerostomia, and age were determined to be significantly associated with fatigue severity after adjusting for depression/anxiety, OSDI score, and the presence of fibromyalgia using a multivariate general linear model. The ESSPRI fatigue score was correlated with the EQ-5D by time trade-off (TTO) values and visual analogue scale (VAS) scores. CONCLUSIONS: In Korean patients with pSS, younger age, xerostomia, and pain were correlated significantly with fatigue, and fatigue was associated with HRQoL.


Subject(s)
Fatigue/etiology , Sjogren's Syndrome/complications , Age Factors , Cohort Studies , Fatigue/epidemiology , Female , Humans , Male , Middle Aged , Pain/etiology , Quality of Life , Republic of Korea/epidemiology , Sjogren's Syndrome/epidemiology , Xerostomia/etiology
7.
Lupus ; 24(12): 1300-7, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26038343

ABSTRACT

This study was performed to investigate the clinical characteristics of lupus cystitis and determine the risk factors and clinical outcomes of lupus cystitis in patients with systemic lupus erythematosus (SLE). We retrospectively reviewed 1064 patients at Seoul St. Mary's Hospital in Seoul, Korea, from 1998 to 2013. Twenty-four patients had lupus cystitis. Lupus cystitis was defined as unexplained ureteritis and/or cystitis as detected by imaging studies, cystoscopy, or bladder histopathology without urinary microorganisms or stones. Three-fourths of patients with lupus cystitis had concurrent lupus mesenteric vasculitis (LMV). The initial symptoms were gastrointestinal in nature for most patients (79.2%). High-dose methylprednisolone was initially administered to most patients (91.7%) with lupus cystitis. Two patients (8.3%) died of urinary tract infections. Sixty-five age- and sex-matched patients with SLE who were admitted with other manifestations were included as the control group. Patients with lupus cystitis showed a lower C3 level (p = 0.031), higher SLE Disease Activity Index score (p = 0.006), and higher ESR (p = 0.05) upon admission; more frequently had a history of LMV prior to admission (p < 0.001); and less frequently had a history of neuropsychiatric lupus (p = 0.031) than did patients with SLE but without lupus cystitis. The occurrence of lupus cystitis was associated with a history of LMV (OR, 21.794; 95% CI, 4.061-116.963). The median follow-up period was 3.4 years, and the cumulative one-year mortality rate was 20%. Complications developed in 33.3% of patients with lupus cystitis and were related to survival (log-rank p = 0.021). Our results suggest that the possibility of lupus cystitis should be considered when a patient with SLE and history of LMV presents with gastrointestinal symptoms or lower urinary tract symptoms. Development of complications in patients with lupus cystitis can be fatal. Thus, intensive treatment and follow-up are needed, especially in the presence of complications.


Subject(s)
Cystitis/etiology , Lupus Erythematosus, Systemic/complications , Vasculitis/complications , Adult , Cystitis/drug therapy , Female , Gastrointestinal Diseases/complications , Humans , Kaplan-Meier Estimate , Lupus Erythematosus, Systemic/drug therapy , Methylprednisolone/therapeutic use , Republic of Korea , Retrospective Studies , Risk Factors , Tomography, X-Ray Computed , Young Adult
8.
Lupus ; 24(7): 764-72, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25712250

ABSTRACT

We investigated obstetric outcomes and comorbidities during pregnancy in females with preexisting lupus nephritis (LN) and identified predictors for renal flare. In cases of renal flare during pregnancy, we assessed the long-term post-delivery renal outcome. We performed a retrospective analysis of 183 systemic lupus erythematosus (SLE) pregnancies including blood chemistry, urinalysis, urinary protein, and disease activity recorded at prepregnancy, during pregnancy, and at one month, six months, and one year post-delivery. Pregnancies with preexisting LN had a greater frequency of adverse obstetric outcomes and maternal comorbidity. Renal flares occurred in 50.7% of pregnancies with preexisting LN, 89.2% of which were reactivations. Renal flare among pregnancies with SLE was predicted based on preexisting lupus nephritis (OR 17.73; 95% CI, 5.770-54.484), an active disease prior to pregnancy (OR 2.743; 95% CI, 1.074-7.004), and prepregnancy eGFR < 90 ml/min/1.73 m(2) (OR 11.151; 95% CI, 3.292-37.768). Persistent LN one year after delivery was observed in 33.3% of pregnancies. The median follow-up time after delivery was 5.9 (3.1-9.7) years and chronic kidney disease (CKD) occurred in 21.4% of pregnancies with renal flare. In patients with renal flare, failing to achieve a ≥ 50% reduction in urine protein levels within six months, longer total duration of renal flare, and acute kidney injury at renal flare was associated with CKD development. Females with preexisting LN should achieve remission before pregnancy. When patients experience renal flares during pregnancy, it is important to reduce the proteinuria level by >50% within six months and to achieve early remission for excellent long-term renal outcomes.


Subject(s)
Lupus Nephritis/physiopathology , Pregnancy Complications/physiopathology , Pregnancy/blood , Pregnancy/urine , Adult , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Lupus Nephritis/blood , Lupus Nephritis/drug therapy , Lupus Nephritis/urine , Pregnancy/statistics & numerical data , Pregnancy Complications/blood , Pregnancy Complications/drug therapy , Pregnancy Complications/urine , Pregnancy Outcome , Republic of Korea , Retrospective Studies
9.
Lupus ; 24(2): 210-7, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25305214

ABSTRACT

We investigated the clinical and laboratory characteristics of pregnancies with systemic lupus erythematosus (SLE) and identified lupus flare predictors during pregnancy. Additionally, we examined lupus activity and pregnancy outcomes in SLE patients who continued, discontinued or underwent no hydroxychloroquine (HCQ) treatment during pregnancy. We retrospectively analyzed 179 pregnancies in 128 SLE patients at Seoul St. Mary's Hospital, Korea, between 1998 and 2012 and then assessed the clinical profiles and maternal and fetal outcomes. Overall, 90.5% of pregnancies resulted in a successful delivery and were divided into two groups: those who experienced lupus flares (80 pregnancies, 44.7%) and those who did not (99 pregnancies, 55.3%). Increased preeclampsia, preterm births, low birth weight, intrauterine growth restriction (IUGR), and low 1-minute Apgar scores occurred in pregnancies with lupus flares compared to pregnancies in quiescent disease. Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels. Our study indicates that achieving pre-pregnancy remission and continuing HCQ treatment during pregnancy are important for preventing lupus flares.


Subject(s)
Hydroxychloroquine/therapeutic use , Lupus Erythematosus, Systemic/physiopathology , Pregnancy Complications/physiopathology , Pregnancy Outcome , Adult , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/therapeutic use , Apgar Score , Female , Fetal Growth Retardation/epidemiology , Follow-Up Studies , Humans , Hydroxychloroquine/administration & dosage , Infant, Newborn , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Lupus Nephritis/epidemiology , Pre-Eclampsia/epidemiology , Pregnancy , Pregnancy Complications/drug therapy , Premature Birth/epidemiology , Republic of Korea , Retrospective Studies , Uric Acid/blood
10.
J Appl Microbiol ; 118(3): 718-26, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25494714

ABSTRACT

AIMS: This study aimed to investigate the potential of Bacillus methylotrophicus as a probiotic. METHODS AND RESULTS: A Bacillus isolate designated strain C14 was isolated from Korean traditional fermented soybean paste (doenjang). The strain was identified, and its physiological and biochemical properties were characterized. The gastrointestinal tolerance and immunomodulatory function of strain C14 were also investigated. Strain C14 was identified as B. methylotrophicus by analysis of its biochemical properties using the API 50CHB system and by phylogenetic analysis of the 16S rDNA sequence. Strain C14 showed >80% and >75% of survival for artificial gastric juices (pH 2.5 and 1% pepsin) and 0.5% (w/v) bile salt, respectively. Heat-killed B. methylotrophicus C14 inhibited the adhesion of various pathogens and enhanced the adhesion of probiotic bacteria to Caco-2 cells. The heat-killed cells also induced high levels of immune cell proliferation compared with the control and stimulated interleukin-6 and tumour necrosis factor-α production in mouse macrophages. CONCLUSIONS: Bacillus methylotrophicus C14 could be used as a probiotic. SIGNIFICANCE AND IMPACT OF THE STUDY: Recently identified B. methylotrophicus is a new potential probiotic with high gastrointestinal tolerance.


Subject(s)
Bacillus/physiology , Probiotics , Soy Foods/microbiology , Animals , Bacillus/classification , Bacillus/isolation & purification , Bile Acids and Salts , Caco-2 Cells , Female , Fermentation , Gastrointestinal Tract/microbiology , Humans , Interleukin-6/biosynthesis , Macrophages/immunology , Mice , Molecular Sequence Data , Peyer's Patches/immunology , Probiotics/isolation & purification , Tumor Necrosis Factor-alpha/biosynthesis
11.
Appl Biochem Biotechnol ; 157(3): 420-30, 2009 Jun.
Article in English | MEDLINE | ID: mdl-18685815

ABSTRACT

To evaluate the commercial potential of new microbial feed additive, Issatchenkia orientalis Y266 and Bacillus subtilis B266 from commercial fermented rice bran were tested for their tolerance or resistance to pH, bile, oxgall, and temperature. It was found that the strains grew very well up to pH 3.0 and resistant to relatively high concentrations of bile salt and oxgall. I. orientalis and B. subtilis are extremely tolerant in range of 70-90 degrees C in solid medium. B. subtilis B266 also has excellent tolerant property up to 90 degrees C in liquid medium. The health indexes (the microflora in the small intestines and the antibody titer to Newcastle disease virus) of chicks were significantly improved in the fermented rice bran with these strains (0.25% addition to diet) in comparison with the Avilamycin (20 mg/kg diet)-fed group (p < 0.05). The fermented rice bran-fed group showed a better microbial flora in the small intestines. Accordingly, it would appear that the fermented rice bran with these strains may be a potential candidate for an alternative microbial feed additive.


Subject(s)
Animal Feed/microbiology , Fermentation , Oryza/microbiology , Seeds/microbiology , Animals , Bacillus subtilis/growth & development , Bacillus subtilis/isolation & purification , Chickens , Hydrogen-Ion Concentration , Intestine, Small/microbiology , Saccharomycetales/growth & development , Saccharomycetales/isolation & purification , Temperature
12.
Diabet Med ; 25(4): 469-75, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18346161

ABSTRACT

AIMS: To investigate associations between gamma-glutamyltransferase (GGT) and components of metabolic syndrome (MS), insulin resistance and inflammatory markers in the Korean population. METHODS: The 3508 subjects enrolled in this survey participated in the Korean Rural Genomic Cohort (KRGC) study. Written consent was obtained from the local ethical committee. Of these participants, 1437 were men (mean age 56.9 +/- 7.9 years) and 2071 were women (mean age 55.8 +/- 8.1 years). We measured GGT levels and various biochemical markers. To examine insulin resistance status, we used the homeostasis assessment method for insulin resistance (HOMA-IR). For inflammatory marker, we used C-reactive protein (CRP) levels. RESULTS: Serum GGT levels were significantly higher in the MS group compared to the healthy patient group [23 (5-1403) vs. 19 (5-1920) IU/l; P = 0.01]. The prevalence of MS and adjusted relative risk were both significantly increased from the lowest to highest GGT quartiles; these results persisted after adjustments for multiple confounders. Positive correlations were established between GGT and HOMA-IR or CRP. CONCLUSION: These results suggest that GGT levels may be a surrogate marker of insulin resistance, inflammation and MS.


Subject(s)
Blood Glucose/metabolism , C-Reactive Protein/metabolism , Metabolic Syndrome/enzymology , gamma-Glutamyltransferase/metabolism , Adult , Biomarkers/metabolism , Body Mass Index , Female , Humans , Insulin Resistance/ethnology , Insulin Resistance/physiology , Male , Middle Aged , Obesity/ethnology , Obesity/metabolism
13.
Bioresour Technol ; 98(1): 165-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16387491

ABSTRACT

The molecular weight of exo-biopolymer obtained from a submerged culture of Cordyceps sinensis 16 consisted of a main unit and a subunit of 126 and 68 kDa, respectively. The optimal medium for the production of mycelia and exo-biopolymer was determined to be molasses containing 2% sucrose, 0.9% yeast extract, 0.3% K2HPO4, and 0.4% CaCl2. Using optimized medium, maximum productions of mycelia and exo-biopolymer in shake-flask culture were 54.0 g/L and 28.4 g/L, respectively. This study suggests that large-scale production of mycelia and exo-biopolymer by C. sinensis 16 is possible in submerged culture.


Subject(s)
Biopolymers/metabolism , Cordyceps/metabolism , Molasses , Mycelium/growth & development , Culture Media , Time Factors
14.
Lett Appl Microbiol ; 35(1): 47-51, 2002.
Article in English | MEDLINE | ID: mdl-12081549

ABSTRACT

AIMS: The objective of the present study was to examine for the various biological activities for feed additives of Saccharomyces cerevisiae and fermented rice bran. METHODS: The feed additives (100 g of each: YE, brewery yeast; PM, mixture of YE and SF; SF, fermented rice bran) were decocted with 2 l water at 100 degrees C to a half volume. RESULTS: The hot-water extract of PM was found to increase the stimulation of the macrophage activation (2.0-fold) and the intestinal immune modulating activity (1.8-fold), compared with those of control. When the hot-water extracts of PM, SF and YE were fed to the rats for 8 d (1 g kg-1 d-1), PM and SF showed the more effective anti-stress effect on spleen, thyroid and thymus gland. SIGNIFICANCE AND IMPACT OF THE STUDY: The hot-water extract of PM can have a significant impact on strengthening the living body's immune system and proliferating anti-stress activities with relation to enhance immunity.


Subject(s)
Adrenal Cortex/metabolism , Oryza/metabolism , Saccharomyces cerevisiae/metabolism , Adrenal Cortex/cytology , Adrenal Glands/metabolism , Animal Feed/microbiology , Animals , Fermentation , Immobilization , Macrophage Activation , Male , Mice , Mice, Inbred C3H , Rats , Rats, Sprague-Dawley , Spleen/metabolism , Thymus Gland/metabolism , Thyroid Gland/metabolism
15.
Org Lett ; 3(8): 1233-6, 2001 Apr 19.
Article in English | MEDLINE | ID: mdl-11348202

ABSTRACT

[reaction: see text]. Catalysis of the glyoxylate-ene reaction by dicationic P2Pt(II) complexes is subject to anion-dependent additive effects. For [((S)-MeOBiphep)Pt](OTf)2 catalysts, acidic phenols such as 3-CF3-C6H3OH or C6F5OH provide substantial rate increases but do not affect the more active SbF6-based catalysts. Enantioselectivity and reactivity also increased with diphosphine basicity, with 4-t-Bu-substituted MeOBiphep ligands yielding the highest enantioselectivities.


Subject(s)
Phosphines/chemistry , Platinum/chemistry , Anions , Ions , Ligands , Models, Chemical , Phenol/chemistry
16.
Biosci Biotechnol Biochem ; 65(10): 2294-6, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11758925

ABSTRACT

The anti-stress and anti-fatigue effects on rats and mice of a hot water extract of rice bran fermented with Saccharomyces cerevisae IFO 2346 were investigated. Oral administration (1 g/kg/day) of the hot water extract of fermented rice bran (FRB) inhibited major changes in the weight of the adrenal, thymus, spleen and thyroid, showing an anti-stress effect. The hot water extract of FRB also inhibited increases in the GPT and LDH activity, cholesterol and glucose in the serum. The administration (1 g/kg/day) for 2 weeks significantly prolonged the swimming time, resulting in an increase in the anti-fatigue effect. It is considered from these results that FRB had anti-stress and anti-fatigue effects.


Subject(s)
Fatigue/prevention & control , Glucans/pharmacology , Stress, Physiological/prevention & control , Adjuvants, Immunologic/metabolism , Adjuvants, Immunologic/pharmacology , Alkyl and Aryl Transferases/blood , Animals , Anthraquinones/blood , Blood Glucose/metabolism , Cholesterol/blood , Disaccharides/blood , Glucans/metabolism , L-Lactate Dehydrogenase/blood , Male , Mice , Mice, Inbred ICR , Organ Size , Rats , Rats, Sprague-Dawley , Swimming , Transferases (Other Substituted Phosphate Groups)/blood
17.
Int J Clin Pharmacol Ther ; 39(12): 539-45, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11770835

ABSTRACT

OBJECTIVE: To comparre the safety and efficacy of naproxen CR (1,000 mg once daily) with that of nabumetone (1,000 mg once daily) in the treatment of patients with symptomatic knee osteoarthritis(OA). METHODS: A total of 159 Korean patients (80 in the naproxen CR group and 79 in the nabumetone group) were enrolled in this 4-week, single-blind, controlled, randomized, parallel study and an intention-to-treat model was used for data analysis. Six efficacy parameters were measured: Lequesne index, visual analogue pain scale at rest and atactivity, patient's and physician's global assessment, and time to walk 50 feet. RESULTS: Significant improvement in all efficacy parameters except time to walk 50 feet occurred at Week 2 and Week 4 in both groups. Themean improvement from baseline at Week 2 and Week 4 for the efficacy variables was not different between naproxen CR and nabumetone group. Twenty-four patients (30%) in the naproxen CR group and 18 patients (22.8%) in the nabumetone group withdrew from the study. Among them, only 1patient in the naproxen CR group terminated the study prematurely due to an adverse event of dyspepsia. No statistically significant difference in the frequency of adverse events, including gastrointestinal symptoms, was observed between these 2 groups during the treatment period. Significant laboratory abnormalities also did not occur during the study period in both groups. CONCLUSIONS: Naproxen CR is an effective and tolerable drug in the treatment of knee OA. Efficacy and safety profiles are comparable to those of nabumetone.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Butanones/therapeutic use , Naproxen/therapeutic use , Osteoarthritis, Knee/drug therapy , Activities of Daily Living , Aged , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Butanones/administration & dosage , Butanones/adverse effects , Constipation/chemically induced , Female , Humans , Male , Middle Aged , Nabumetone , Naproxen/administration & dosage , Naproxen/adverse effects , Nausea/chemically induced , Pain Measurement , Single-Blind Method , Treatment Outcome , Walking
18.
Scand J Rheumatol ; 29(5): 288-94, 2000.
Article in English | MEDLINE | ID: mdl-11093594

ABSTRACT

Pulmonary alveolar hemorrhage (PAH) is a rare and often fatal presenting feature of rheumatic diseases, with high mortality rate ranging from 40% to 90%. This study was undertaken to review the clinical manifestations, disease course, prognosis, and treatment of PAH in rheumatic diseases in Korea. A retrospective analysis was performed from October 1995 to March 1999 at the Samsung Medical Center. Ten cases were diagnosed as having pulmonary hemorrhage with rheumatic diseases that comprised the following: 6 systemic lupus erythematosus (SLE), 3 microscopic polyangiitis (MPA), and 1 mixed connective tissue disease (MCTD). In 80% of the patients in the present series, PAH was the first clinical manifestation of rheumatic diseases. The most consistent systemic manifestation occurring in conjunction with PAH was renal involvement (80%). The overall patient mortality rate was 50% (5/10) in the current series. Our study suggests that PAH often occurs as the first clinical manifestation of rheumatic diseases and needs urgent medical treatment including plasmapheresis in addition to cyclophosphamide and methylprednisolone.


Subject(s)
Hemorrhage/etiology , Lung Diseases/etiology , Pulmonary Alveoli/pathology , Rheumatic Diseases/complications , Adult , Aged , Cyclophosphamide/therapeutic use , Female , Hemorrhage/diagnosis , Hemorrhage/mortality , Hemorrhage/therapy , Humans , Korea/epidemiology , Lung Diseases/diagnosis , Lung Diseases/mortality , Lung Diseases/therapy , Male , Methylprednisolone/therapeutic use , Middle Aged , Plasmapheresis , Radiography, Thoracic , Retrospective Studies , Rheumatic Diseases/diagnosis , Rheumatic Diseases/mortality , Rheumatic Diseases/therapy , Survival Rate
19.
Org Lett ; 2(16): 2487-90, 2000 Aug 10.
Article in English | MEDLINE | ID: mdl-10956528

ABSTRACT

Ketones were asymmetrically transformed to chiral acetates by one-pot processes using a lipase and an achiral ruthenium complex under 1 atm of hydrogen gas in ethyl acetate. Molecular hydrogen was also effective for the transformation of enol acetates to chiral acetates without additional acyl donors with the same catalyst system.


Subject(s)
Acetates/chemistry , Acetates/chemical synthesis , Ketones/chemistry , Lipase , Ruthenium , Indicators and Reagents , Isomerism , Structure-Activity Relationship
20.
Org Lett ; 2(15): 2377-9, 2000 Jul 27.
Article in English | MEDLINE | ID: mdl-10930288

ABSTRACT

An enzyme-metal combo reaction has been developed for the dynamic kinetic resolution of allylic alcohols in which racemic substrates are transformed by a lipase and a ruthenium complex in the presence of an acyl donor to allylic acetates of high optical purity in over 80% yield.


Subject(s)
Lipase/metabolism , Propanols/chemical synthesis , Ruthenium Compounds/metabolism , Catalysis , Enzymes, Immobilized/metabolism , Kinetics , Propanols/chemistry , Propanols/metabolism , Pseudomonas/enzymology , Stereoisomerism
SELECTION OF CITATIONS
SEARCH DETAIL
...